Cite
Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.
MLA
Bäck, Tom A., et al. “Targeted Alpha Therapy with Astatine-211-Labeled Anti-PSCA A11 Minibody Shows Antitumor Efficacy in Prostate Cancer Xenografts and Bone Microtumors.” EJNMMI Research, vol. 10, no. 1, Feb. 2020, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s13550-020-0600-z.
APA
Bäck, T. A., Jennbacken, K., Hagberg Thulin, M., Lindegren, S., Jensen, H., Olafsen, T., Yazaki, P. J., Palm, S., Albertsson, P., Damber, J.-E., Wu, A. M., & Welén, K. (2020). Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research, 10(1), 1–12. https://doi.org/10.1186/s13550-020-0600-z
Chicago
Bäck, Tom A., Karin Jennbacken, Malin Hagberg Thulin, Sture Lindegren, Holger Jensen, Tove Olafsen, Paul J. Yazaki, et al. 2020. “Targeted Alpha Therapy with Astatine-211-Labeled Anti-PSCA A11 Minibody Shows Antitumor Efficacy in Prostate Cancer Xenografts and Bone Microtumors.” EJNMMI Research 10 (1): 1–12. doi:10.1186/s13550-020-0600-z.